Angelini Ventures

We focus on investment opportunities within the healthcare and life science markets where we can identify value early. At the core of our investment philosophy is a committed and collaborative approach to working with management teams and syndicate partners to build successful companies. We work actively with founders, providing guidance, support and access to our network. We strongly believe that no two investments are the same and support the most suitable business model for each individual venture, working with management teams to formulate strategies to achieve financial independence. We are comfortable financing companies by ourselves and, if appropriate, working closely with the founders to help build a syndicate of co-investors who bring complementary relationships and share our vision. We have a 14-year history of continuous dedication to the fast growing MedTech sector and a history of backing successful entrepreneurs transforming healthcare through MedTech innovation. Investment Strategy Focus: Within the broader healthcare market, we focus our investments on medical technologies including medical devices, diagnostics, drug delivery, and digital health. We back both first-time and experienced founders, who value our participation as well our capital. Stage: We are typically the first institutional investor and support companies through early product and clinical development and often through the regulatory process. We make our first investment at the seed through series B stage, based on when the risk of translation from pre-clinical to clinical is at its lowest. We are life cycle investors and continue to support our portfolio companies through to exit. Capital Efficiency: We invest in companies that are able to demonstrate early and meaningful clinical value with minimum capital invested and preserve the most appropriate exit opportunity. Therapeutic Indications: While we are agnostic to therapeutic indication, we invest in companies developing products that address large, global markets and where there is significant unmet clinical need. We particularly like therapeutic devices that significantly improve patient outcomes and diagnostics that fundamentally change the course of therapeutic intervention.

DaVita Venture Group is committed to building partnerships with health care innovators to help improve the lives of patients with kidney disease and related conditions. Together, we believe we can transform the future of patient care for the better. Our Strategy We aim to invest in, acquire, and co-develop products, solutions and businesses that improve care for patients with kidney disease and related conditions. PrioritiesCare Delivery Models: Advancements to expand access to care and improve clinical outcomes through adoption of tech-enabled services, home treatments and value-based care Life Sciences: Pharmaceuticals, medical devices and diagnostics that can improve clinical outcomes and patient experience while reducing costs Digital Health: Products and services that leverage technology, data and connectivity to improve care delivery

As part of our investment approach, we developed a structured evaluation process, the “FemHealth Framework.” The first element (re)imagines women’s health as conditions appearing only in women, mostly in women, and differently in women. This concept from the FemHealth Framework (© 2019 FemHealth Ventures) was first published in 2019 and is increasingly thought of as a new lens through which to view women’s health. At FemHealth Ventures, we are excited about the increasing adoption of this broader definition of women’s health and the exciting new treatments it will engender. Only in Women Some conditions appear only in women. Examples include: endometriosis polycystic ovarian syndrome cervical cancer Mostly in Women Some conditions appear mostly in women. Examples include: breast cancer lupus multiple sclerosis Differently in Women Some conditions appear differently in women. Examples include: heart disease diabetes asthma Every cell has a sex A universe of possibilities is opened in women’s health when we start with the most basic building block: our cells. Each of the 30 trillion cells in a woman’s body has a different chromosomal makeup than a man. For example, a skin cell from a woman will have XX chromosomes, but a skin cell from a man will have XY chromosomes. This difference between women and men holds true throughout every single cell in the body. As a result, even the same disease can present differently in women versus men and require distinct treatment paradigms. Women’s health is more than “bikini medicine.” The term “bikini medicine” generally refers to conditions treated by obstetricians or gynecologists. We’ve (re)imagined women’s health as a broad spectrum of conditions that can impact the whole body, ranging from ovarian cancer, to autoimmune disease, to cardiovascular disease, and everything in between. A multitude of possibilities for innovation in women’s health exist. And we are here to help bring them to life.

Noetic invests globally to build emerging technologies in molecular therapeutics/biotech, digital health, medical devices, and wellness with a focus on mental health, pain, and other complications resulting from the central nervous system. About no•et•ic “From the Greek noēsis/ noētikos meaning inner wisdom, direct knowing, or subjective understanding” Noetic science refers to a multidisciplinary field that brings objective scientific tools and techniques together with subjective understanding to study the full range of human experience. Mission: Our mission is to nurture the scientific advancement of mental, emotional, and physiological health by investing in emerging therapies, modalities, and sciences that are committed to optimizing our human experience. Commitment: We are committed to developing sustainable therapies, products, and services that are innovative, safe, and accessible to create a better mental health landscape for current and future generations. Focus: CNS-targetted therapeutics and related sustainable solutions for mental health and physical well being.

Cross-Border Impact Ventures is an impact venture capital firm on a mission to revolutionize venture capital investing in health technology. We work with visionary teams to leapfrog access to world leading affordable technologies for women, children and adolescents. Health technologies are more scalable than ever before. The time is now to take a global tailored approach in this sector. OUR INVESTMENT UNIVERSE We look for audacious companies commercializing globally relevant medical devices, diagnostics, therapeutics and digital health innovations that are prioritizing huge market opportunities in women, children and adolescent health. We value real world and clinical data. We focus on 4 key sectors: Sexual and reproductive health, Maternal, newborn and child health, General health, including chronic diseases, and Health software infrastructure. We invest in companies addressing gender health inequalities. Positive impact and financial returns are not mutually exclusive. We seek opportunities that offer both high impact & high returns. OUR IMPACT We believe good health is a right that should not be restricted by gender, age, race, wealth and borders. We hold ourselves to the highest standard of impact investing and implement recognized impact management processes. We invest with a gender and diversity lens. WE ARE ENABLERS We are specialists in women, children and adolescent health with deep expertise in health technology. We are hands-on investors and support our exceptional management teams with access to new markets, unique forms of capital and health technology expertIse in North America, Europe as well as global markets. WE UNLOCK GLOBAL IMPACT OPPORTUNITIES Cutting edge technologies take decades to reach underserved communities. We work with management teams to fast track the process.

Canada’s leading digital healthcare Venture Capital firm, offering local depth with global reach. We are healthcare practitioners, operators and founders with over 100 years’ experience and a deep network. We focus on early stage and high-growth companies shaping the future of healthcare delivery and empowering them to scale and grow. How We InvestStage: Investments will be in early stage companies ranging from pre-Seed rounds through pre-IPO with initial investments focused on Seed and Series A rounds Areas: We look for groundbreaking HealthTech ideas focusing on digitization of healthcare, emergence of consumer MedTech, and consumerization of health and wellness Locations: We invest primarily in companies located in Canada, the US and Israel that target markets in North America and Europe